Outlook Therapeutics (NASDAQ:OTLK - Free Report) had its price target trimmed by Ascendiant Capital Markets from $35.00 to $33.00 in a research report report published on Tuesday, Benzinga reports. The firm currently has a buy rating on the stock.
A number of other analysts have also commented on OTLK. HC Wainwright reiterated a buy rating and set a $30.00 price target on shares of Outlook Therapeutics in a report on Thursday, August 15th. Chardan Capital reissued a buy rating and set a $53.00 target price on shares of Outlook Therapeutics in a report on Friday, August 16th. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Outlook Therapeutics has an average rating of Buy and a consensus target price of $48.20.
Read Our Latest Analysis on OTLK
Outlook Therapeutics Trading Down 8.3 %
OTLK stock traded down $0.61 during trading on Tuesday, reaching $6.74. 343,360 shares of the stock were exchanged, compared to its average volume of 364,578. Outlook Therapeutics has a twelve month low of $4.00 and a twelve month high of $18.00. The firm's 50 day moving average is $7.66 and its 200 day moving average is $7.97. The firm has a market cap of $159.47 million, a P/E ratio of -0.59 and a beta of 0.71.
Institutional Investors Weigh In On Outlook Therapeutics
A number of large investors have recently modified their holdings of OTLK. Rosalind Advisors Inc. bought a new stake in Outlook Therapeutics in the first quarter worth $3,723,000. Great Point Partners LLC lifted its position in shares of Outlook Therapeutics by 15.0% during the 2nd quarter. Great Point Partners LLC now owns 1,701,510 shares of the company's stock valued at $12,557,000 after buying an additional 221,510 shares in the last quarter. LVW Advisors LLC purchased a new stake in Outlook Therapeutics during the 2nd quarter valued at approximately $352,000. Susquehanna Fundamental Investments LLC bought a new stake in Outlook Therapeutics during the second quarter worth approximately $303,000. Finally, Squarepoint Ops LLC purchased a new position in Outlook Therapeutics during the 2nd quarter valued at $232,000. Institutional investors own 11.20% of the company's stock.
About Outlook Therapeutics
(
Get Free Report)
Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.
Read More
Before you consider Outlook Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Outlook Therapeutics wasn't on the list.
While Outlook Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
